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Abstract
Purpose—We use simulations and an empirical example to evaluate the performance of disease 
risk score (DRS) matching compared with propensity score (PS) matching when controlling large 
numbers of covariates in settings involving newly introduced treatments.
Methods—We simulated a dichotomous treatment, a dichotomous outcome, and 100 baseline 
covariates that included both continuous and dichotomous random variables. For the empirical 
example, we evaluated the comparative effectiveness of dabigatran versus warfarin in preventing 
combined ischemic stroke and all-cause mortality. We matched treatment groups on a historically 
estimated DRS and again on the PS. We controlled for a high-dimensional set of covariates using 
20% and 1% samples of Medicare claims data from October 2010 through December 2012.
Results—In simulations, matching on the DRS versus the PS generally yielded matches for more 
treated individuals and improved precision of the effect estimate. For the empirical example, PS 
and DRS matching in the 20% sample resulted in similar hazard ratios (0.88 and 0.87) and 
standard errors (0.04 for both methods). In the 1% sample, PS matching resulted in matches for 
only 92.0% of the treated population and a hazard ratio and standard error of 0.89 and 0.19, 
respectively, while DRS matching resulted in matches for 98.5% and a hazard ratio and standard 
error of 0.85 and 0.16, respectively.
Conclusions—When PS distributions are separated, DRS matching can improve the precision of 
effect estimates and allow researchers to evaluate the treatment effect in a larger proportion of the 
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treated population. However, accurately modeling the DRS can be challenging compared with the 
PS.
INTRODUCTION
Evaluating the comparative effectiveness of newly introduced treatments presents unique 
challenges in pharmacoepidemiologic research. The propensity score, defined as the 
conditional probability of treatment given a set of observed covariates, has become a 
standard tool for controlling large numbers of confounding variables.1, 2 However, 
accurately modeling the PS for a new treatment can be difficult if the treated population is 
small or factors affecting treatment assignment change rapidly.3, 4
In a recent paper, Glynn et al.3 proposed using an alternative covariate summary score, the 
disease risk score (DRS), to control for confounding in settings involving new treatments. 
Glynn et al. argued that factors affecting disease risk are more likely to be stable over time 
than are factors affecting treatment, potentially simplifying the estimation of the DRS 
compared with a time-varying PS. While the DRS can be more stable over time, modeling 
the DRS in practice also presents unique challenges that are not shared by the PS. Unlike the 
PS which models covariate associations with treatment, the DRS models covariate 
associations with the potential outcome under the control or comparator treatment.5 In 
practice, however, this potential outcome is not observed for all individuals in the study 
population, but only for those receiving the comparator treatment. Consequently, the DRS 
must be modeled indirectly for treated individuals.
The DRS has typically been estimated in one of two ways. The first is to fit a regression 
model within the cohort of individuals receiving the comparator treatment and then 
extrapolate this model to predict disease risk for the full cohort. The second is to fit a 
regression model within the full cohort as a function of baseline covariates and treatment 
and then estimate the disease risk for each individual after setting treatment status to 
zero. 3, 5–8 Hansen discussed limitations to both of these strategies, which have been termed 
“same-sample” estimation.5
Fitting the DRS to the full cohort benefits from increased sample size, but introduces 
additional complexity as it requires accurately modeling the relation between treatment and 
outcome. Small misspecifications in the full-cohort DRS model can introduce bias by 
resulting in estimated scores that are non-ancillary or carry information about the treatment 
effect.5, 9 Consequently, Hansen5 recommends using only the control population when 
fitting the DRS model. Leacy and Stuart9 explained that using only the control population 
when modeling the DRS tends to result in estimated scores that are more robust to model 
misspecification. Fitting the DRS only among individuals receiving the comparator 
treatment, however, can lead to overfitting, which results in overestimating disease risk for 
high-risk comparator patients and underestimating disease risk for low-risk comparator 
patients.3, 5 Such overfitting can lead to apparent treatment effect heterogeneity over the 
distribution of disease risk and potentially bias overall effect estimates.3, 5
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To circumvent the problems of same-sample estimation, both Hansen5 and Glynn et al.3 
have proposed using controls from a period prior to the current study to fit the DRS model. 
Glynn et al. suggested that estimating the DRS with historical data can be particularly 
advantageous in pharmacoepidemiologic studies using large administrative healthcare 
databases to evaluate newly introduced treatments or evolving drug therapies. Modeling the 
DRS with historical data can avoid the problems associated with “same-sample” estimation, 
but can also result in fitted risk models that are not generalizable to the study population. 
This strategy assumes that the effects of risk factors on the outcome, surveillance of 
individuals, and coding practices do not change over time. Violation of these assumptions 
could result in misspecified estimates of disease risk when applied to the study cohort.
Little evidence exists to confirm the theoretical advantages of a historically estimated DRS 
over a traditional PS when evaluating new treatments. A number of studies have shown that 
simply fitting time-specific PS models can perform well when the indication for treatment 
changes rapidly over time.4, 10 Further, the limitations of the PS when the number of 
exposed individuals is small are not well understood. Previous studies have also shown that 
overfitting the PS model does not necessarily compromise confounding control.11 There 
remain few examples demonstrating the application of a historically estimated DRS when 
evaluating new treatments. Potential advantages and challenges of using DRSs in these 
settings remain unclear.
In this paper, we use both simulations and an empirical example to compare the performance 
of DRS matching with that of PS matching when controlling large numbers of covariates in 
settings involving newly introduced treatments. We discuss both challenges and potential 
advantages of using the DRS for confounding control as well as required assumptions for 
using historical data to model the DRS. We then evaluate the performance of DRS matching 
with PS matching in an empirical example where we compare the new oral anticoagulant 
dabigatran with warfarin in preventing ischemic stroke and all-cause mortality in patients 
diagnosed with atrial fibrillation in the Medicare population.
METHODS
Simulation Study
We simulated a causal scenario that was motivated by an empirical example (described later) 
comparing dabigatran with warfarin in preventing ischemic stroke and all-cause mortality 
among new users. We simulated 100 baseline covariates. As in most pharmacoepidemiologic 
settings, the majority of these baseline covariates were dichotomous (simulated as binomial 
random variables). We simulated a dichotomous treatment and a dichotomous outcome 
according to equations 1 and 2.
[1]
[2]
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We considered scenarios where we varied the sample size and the strength of covariate-
treatment and covariate-outcome associations. We also considered a scenario involving 
treatment effect heterogeneity since, in the presence of heterogeneity, incomplete matching 
can result in an estimand that is different from the average treatment effect in the full treated 
population.12, 13 For all scenarios, values for α0 and β0 in Equations 1 and 2 were selected so 
that the baseline prevalence for both treatment and outcome was 30%.
In scenario 1, we considered a constant treatment effect (βT = 0 and βint = 0) and selected 
values for the coefficients α1 through α100 and β1 through β100 so that the effects of 
covariates on both the treatment and outcome were mild (coefficients values ranging from 
−0.182 to 0.182). In Scenarios 2 and 3, we again considered a constant treatment effect, but 
selected values for the coefficients α1 through α100 and β1 through β100 to allow for 
moderate and strong effects, respectively, on the treatment and outcome (coefficient values 
ranging from −0.405 to 0.405 for moderate effects, and from −0.693 to 0.693 for strong 
effects). In Scenario 4 we selected values for the coefficients to allow for moderate effects 
on both the treatment and outcome, but also included treatment effect heterogeneity by 
setting βint= 0.693.
We allowed coefficients to be both positive and negative to reflect practical settings where 
baseline covariates induce confounding in both directions. For each scenario, we considered 
sample sizes of 10,000 and 1,000 for a total of eight scenarios. A full description of the 
simulated structure is provided in the Supporting Information.
We modeled the DRS within a simulated historical population of controls and the PS within 
the original simulated cohort. For each scenario, the historical population of controls 
consisted of 10,000 individuals and was simulated to be similar to the original cohort, but 
with no treatment introduced. We estimated both the PS and DRS using logistic regression 
that included main effects for each of the baseline covariates X1 through X100. Because the 
true PS model (Equation 1) and true DRS model (i.e., outcome model in Equation 2 with 
treatment set to 0) were simulated as a function of only the main effects of X1 through X100, 
this simulation compared the PS and DRS in a situation where both the fitted models were 
correctly specified.
We implemented the estimated PSs and DRSs using 1-1 nearest neighbor matching within a 
specified caliper distance. Matching was carried out without replacement. We considered 
two caliper distances. We first followed the recommendation of Rosenbaum and Rubin and 
used a caliper distance of 0.25 standard deviations of the respective PS or DRS distribution 
on the logit scale.14 We then repeated the analysis using a ten-fold decrease in the caliper 
distance of 0.025 standard deviations of the logit of the respective PS or DRS distribution. 
We chose to include a very small caliper distance to observe the sensitivity in the number of 
individuals being matched on the PS versus the DRS as the caliper size is reduced by a 
considerable amount.
We measured the performance of DRS and PS matching by calculating the bias, mean 
squared error (MSE), and precision of the effect estimates. The bias, defined as the expected 
value of the difference between the effect estimate and the true effect, was calculated by 
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taking the mean of this difference over all simulation runs. For scenarios involving treatment 
effect heterogeneity, the true value for the average treatment effect in the treated was 
calculated by simulating the predicted response under both treatment and control for each 
individual in the treated population (i.e., potential outcomes). These potential responses 
were then used to calculate the true value for the average treatment effect in the treated 
population. Details are provided in the Supporting Information. The MSE was calculated by 
taking the mean of the squared bias over all simulation runs. To evaluate precision, we 
estimated the standard error (SE) using the empirical standard deviation of the distribution of 
the treatment-effect estimates across all simulation runs.
Empirical Study: Dabigatran vs. Warfarin in Patients with Atrial Fibrillation
We compared the performance of dabigatran versus warfarin in an elderly population using 
linked Medicare Parts A (hospital), B (outpatient), and D (pharmacy) data. We identified 
eligible individuals from a 20% random sample of Medicare beneficiaries with fee-for-
service enrollment in all three plans for at least one month from October 19, 2010 (when 
dabigatran was introduced) through December 31, 2012. New users were defined as 
individuals who initiated dabigatran or warfarin after a 1-year washout period with no 
prescription for any oral anti-coagulant.15 We required continuous enrollment in Medicare 
for at least 12 months prior to drug initiation. All demographic and clinical covariates 
(described later) were defined during the 12 months prior to drug initiation. Individuals were 
censored only if they lost Medicare enrollment during follow-up (intent-to-treat analysis).
We restricted our study cohort to individuals who were 65 years of age or older and had an 
inpatient or outpatient diagnosis code for atrial fibrillation or atrial flutter (ICD-9 427.31, 
427.32) prior to initiation of dabigatran or warfarin. We excluded individuals with a known 
heart valve replacement because this is a contraindication for dabigatran use. We also 
excluded individuals at a skilled nursing facility at drug initiation.
We modeled the one-year risk of combined ischemic stroke and all-cause mortality within a 
population of new warfarin users with an index date prior to the introduction of dabigatran 
(between January 1, 2008 and October 18, 2010). This model was then used to predict the 
disease risk for all individuals within the study cohort. We also estimated the PS within the 
study cohort for comparison. The PS and DRS models included main effects for 37 
covariates (described later), which were selected a priori using expert knowledge. We added 
200 empirically selected covariates based on Medicare medication claims, inpatient and 
outpatient diagnostic codes, and procedural codes. We identified the 200 most prevalent 
codes within each data dimension using both the historical population of new warfarin users 
and original study cohort of new-users of warfarin and dabigatran (codes with a prevalence 
greater than 0.5 were subtracted from 1). Of the 600 covariates identified in this way, we 
selected the 200 with the strongest univariate associations (odds ratios) with the outcome 
after restricting to individuals receiving the comparator treatment (all new-users of 
warfarin). The estimated PSs and DRSs were implemented using 1-1 nearest neighbor 
caliper matching without replacement. We used the same caliper distances described in the 
simulation study (0.25 and 0.025 standard deviations of the logit of the respective PS or 
DRS distribution). Similar to the simulation study, we repeated the analyses using two 
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different calipers distances to observe the sensitivity in the number of individuals matched 
on the PS versus the DRS as the caliper size is reduced. We estimated the hazard ratio (HR) 
within the matched populations using Cox proportional hazards models.
We conducted analyses using 20 and 1 percent samples of the Medicare data to observe the 
sensitivity of the results as the sample size is reduced. Previous studies have shown that 
confounding can be stronger shortly after a treatment’s introduction.16–18 To observe the 
sensitivity of the results to the duration of follow-up, we repeated the analysis using data 




For simulation scenarios not involving treatment-effect heterogeneity, Figures 1 and 2 show 
the PS and DRS distributions by treatment group for one simulation run with a sample size 
of 10,000 (Figure 1) or 1,000 (Figure 2). The degree of overlap (i.e., area of overlapping 
region) between the DRS distributions was always larger than the degree of overlap between 
the PS distributions. Varying the sample size and the strengths of covariate-treatment and 
covariate-outcome associations affected the overlap in PS distributions more strongly than it 
affected the overlap in DRS distributions (Figures 1 and 2).
Table 1 shows results when matching on the smaller caliper distance of 0.025 standard 
deviations of the logit of the PS or DRS distribution. For every scenario, a larger percentage 
of the treated population could be matched on the DRS versus the PS because of the greater 
overlap in DRS distributions (percent matched was approximately 100 for DRS matching 
and ranged from 96.5 to 54.5 for PS matching). The DRS-matched estimate generally had 
greater precision and lower MSE compared to the PS-matched estimate, with MSE ranging 
from 0.02 to 0.30 for DRS matching and 0.03 to 0.39 for PS matching (Table 1). Both DRS 
and PS matching resulted in approximately unbiased estimates for scenarios where there was 
no treatment effect heterogeneity. In the presence of treatment effect heterogeneity, matching 
on the DRS resulted in a more accurate evaluation of the treatment effect within the entire 
treated population (Table 1). When using a larger caliper distance of 0.25 standard 
deviations of the logit of the PS or DRS distribution, differences in the percent matched and 
standard errors were smaller, but the overall patterns were similar (not shown).
Empirical results
We present results for the empirical study in Figures 3 and 4 as well as Tables 2 and 3. Table 
2 shows the distribution of the 37 a priori selected covariates by treatment group. New users 
of dabigatran were generally healthier, with fewer comorbidities and greater use of the 
healthcare system than new users of warfarin (Table 2). Similar patterns of initiation have 
been found in other studies.19, 20
Figures 3 and 4 show the PS and DRS distributions by treatment group for the 20% (Figure 
3) and 1% (Figure 4) samples of the Medicare data, with follow-up through 2012. In both 
analyses, controlling for the larger set of empirically selected covariates resulted in greater 
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separation in PS distributions while having little impact on the separation in DRS 
distributions.
For the 20% sample (Table 3), approximately 100% of the treated population was matched 
on the PS and the DRS, regardless of the caliper distance or number of covariates included 
in the models. In this case, both PS and DRS matching resulted in similar hazard ratios and 
standard errors, both when controlling for the covariates selected a priori (HRs 0.75 and 0.73 
respectively; SEs both 0.03) and after adding the empirically selected covariates (HRs 0.88 
and 0.87 respectively; SEs both 0.04).
When using the 1% sample of the Medicare data and controlling for the covariates selected a 
priori (Table 3), PS and DRS matching yielded similar results, with approximately 100% of 
the treated population being matched for both methods and caliper distances (HR and SE of 
0.75 and 0.14 for PS matching and 0.74 and 0.14 for DRS matching). However, when 
controlling for the expanded covariate set in this sample and matching on the smaller caliper 
distance, only 92% of the treated patients were matched on the PS, compared to 
approximately 99% on the DRS (Table 3). The reduction in the percentage matched resulted 
in reduced precision for the PS-matched estimate (SE 0.19 versus 0.16) (Table 3). When 
matching on the larger caliper distance (not shown), the overall patterns were similar except 
the differences in the percent matched on the PS versus the DRS were smaller (e.g., 95.3% 
and 99.9% were matched on the PS and DRS, respectively, when controlling the expanded 
set of covariates with the 1% Medicare sample). In the analyses evaluating treatment effects 
in the first year of dabigatran use (not shown), the pattern of results was similar to that 
shown in Table 3, except that unadjusted and adjusted estimates were further from the null 
and standard errors were larger.
Each of the PS models resulted in good model fit in terms of calibration and discrimination 
for all scenarios (Hosmer-Lemeshow p-value ranging from 0.16 to 0.49; c-statistic ranging 
from 0.68 to 0.79). The PS models also performed well in terms of balancing covariates 
across treatment groups with an average standardized absolute mean difference (ASAMD) 
of 0.01 or less for all scenarios. In terms of predictive performance, the DRS models had 
good discrimination (c-statistic ranging from 0.73 to 0.78), but performed poorly in terms of 
calibration (Hosmer-Lemeshow p-value <0.01 for three out of four scenarios).
DISCUSSION
In this study, we used both simulations and an empirical example to explore potential 
benefits of using a historically estimated DRS when controlling large numbers of covariates 
in settings with newly introduced treatments. With few exposed individuals and smaller 
sample sizes, fitting a high-dimensional PS model can increase separation between the PS 
distributions of the treatment groups, reducing the number of treated individuals who can be 
matched on the PS. In theory, the overlap in DRS distributions across treatment groups 
should always be at least as great as the overlap in PS distributions when the PS and DRS 
models include the same covariates. Therefore, matching on the DRS may allow researchers 
to evaluate the treatment effect within a larger proportion of the treated population, 
compared to matching on the PS.
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This potential for greater overlap in the distribution of disease risk across treatment groups is 
because conditioning on the PS (e.g., matching or stratifying) is more restrictive than 
conditioning on the DRS. PS methods require that there be no combination of covariate 
values that result in individuals receiving treatment or control with certainty (i.e., positivity 
assumption).5, 21, 22 Hansen formally shows that adjustment on the DRS requires a weaker 
condition that there be no levels of disease risk at which treatment or control is received with 
certainty.5 Consequently, adjustment using the DRS can allow researchers to include 
individuals who would otherwise be excluded with PS adjustment. Even when positivity is 
satisfied, conditioning on the PS can still be more restrictive than conditioning on the DRS. 
Balance on the PS will result in covariates being independent of treatment assignment. This 
implies that any function of baseline covariates, including the DRS, will also be independent 
of treatment. Therefore, PS balance across treatment groups implies balance on the DRS in 
expectation. The reverse is not true. Because the DRS does not balance covariates across 
treatment, but only with respect to the potential outcome under control, balance on the DRS 
across treatment does not imply balance on the PS.5 DRS matched treatment groups can 
include the same population of individuals who are balanced on the PS as well as individuals 
who may have differing PS distributions but similar overall risk for the outcome.5
In the simulations, we demonstrated that when there was strong separation in the PS 
distributions across treatment groups, matching on the DRS can result in a larger proportion 
of the treated population being matched, improving the precision of the effect estimate and, 
in the presence of treatment effect heterogeneity, provide more accurate estimates of the 
treatment effect in the full treated population. As with any simulation, results are specific to 
the scenarios considered. In this simulation study, we did not consider unmeasured 
confounding or instrumental variables (i.e., variables that do not affect the outcome except 
through treatment). The inclusion of instruments would have created larger differences in the 
degree of overlap in PS versus DRS distributions and, in the presence of unmeasured 
confounding, resulted in greater bias amplification when matching on the PS versus a 
historically estimated DRS.23
For the empirical example, we found that when there was moderate separation in the PS 
distributions across treatment groups, DRS and PS matching gave similar estimates of the 
effect of the new oral anticoagulant dabigatran versus warfarin in reducing combined 
ischemic stroke and all-cause mortality within the Medicare population. However, when 
controlling for large numbers of covariates with reduced sample size, the separation in the 
PS distribution across treatment groups increased and matching on a historically estimated 
DRS improved the precision of the effect estimate by allowing a larger proportion of the 
treated population to be matched. For both PS and DRS matching, when we added a large 
set of empirically selected covariates, effect estimates became more consistent with the 
results of clinical trials and other studies comparing these treatments within the Medicare 
population.24, 25 When we restricted the analysis to the first year of dabigatran use, estimates 
moved further from the null (becoming less consistent with trial results), likely reflecting the 
strong channeling that occurs shortly after a treatment’s introduction.16–18
With greater overlap in the distribution of disease risk across treatment groups, it is likely 
that for any given study, the optimal caliper distance for matching on the DRS will be 
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smaller than the optimal caliper distance for matching on the PS. For both the simulations 
and empirical example, we found that reducing the caliper distance resulted in fewer 
individuals being matched on the PS while having less of an impact on the number of 
individuals being matched on the DRS. While many studies have discussed the importance 
of choosing an appropriate caliper distance when matching on the PS, more research is 
needed in determining appropriate caliper distances when matching on the DRS.13, 26
While matching on the DRS can allow for a larger portion of individuals to be compared 
across treatment when there is separation in the PS distributions, it is important to consider 
why the PS distributions are separated. If the separation is due to strong differences in 
confounding variables rather than overfitting the PS model, researchers should proceed 
cautiously. Strong differences in measured confounders can indicate strong differences in 
unmeasured confounders, which could be addressed best in the study design phase rather 
than the analysis phase. We stress the importance of reducing differences in the distribution 
of baseline covariates across treatment groups through proper study design (e.g., new-user 
design and other restriction criteria).16, 27
While we have focused on potential benefits of matching on the DRS, the DRS also has 
some theoretical disadvantages compared to the PS. Because the DRS is formally defined in 
terms of a potential outcome, estimating the DRS in practice can be challenging and requires 
additional assumptions. Further, unlike the PS, the DRS cannot be evaluated using measures 
of covariate balance within the full study population. In this study, the estimated PS models 
resulted in good model fit and PS matching balanced covariates across treatment groups. 
When modeling the DRS using historical data, we found it difficult to obtain good model fit 
in terms of the Hosmer-Lemeshow test, particularly when controlling for larger numbers of 
covariates. Other studies have reported similar findings when estimating high-dimensional 
DRSs and have proposed implementing shrinkage methods to reduce the dimensionality of 
covariates to improve model fit.28 For this study, however, poor fit in terms of the Hosmer-
Lemeshow test did not appear to have a strong impact on the performance of the DRS 
compared with the PS. More research is needed to determine how best to estimate and 
evaluate the validity of DRS models.
We conclude that under certain assumptions, using historical data to model the DRS is a 
valid method to control for confounding when evaluating newly marketed drugs. Further, 
when there is strong separation in the distribution of the PS across treatment groups, 
matching on a historically estimated DRS versus a PS can allow researchers to evaluate the 
treatment effect within a larger proportion of the treated population. We further conclude, 
however, that accurately modeling the DRS can be more challenging as compared with 
modeling the PS, even in settings involving newly introduced treatments. When using 
summary scores for confounding control, we recommend conducting and reporting results 
from PS analyses in addition to analyses using a historically estimated DRS.
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• In theory, the degree of overlap in the distribution of disease risk across 
treatment groups will always be at least as large as the overlap in the propensity 
score across treatment groups.
• Controlling for a high-dimensional set of covariates can improve confounding 
control, but increases separation between the PS distributions of the treatment 
groups while having less impact on the separation between the disease risk 
distributions of the treatment groups.
• Matching on the DRS can allow researchers to evaluate the treatment effect 
within a larger proportion of treated individuals, compared to matching on the 
PS. However, accurately modeling the DRS can be challenging compared to the 
PS, even in settings involving newly introduced treatments.
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Propensity score (PS) and disease risk score (DRS) distributions across treatment groups for 
one run of the simulation study with a sample size of 10,000 subjects and 100 covariates 
included in the PS and DRS models. In plots A and B the effects of covariates on both 
treatment and the outcome were mild, in plots C and D covariate effects were moderate, and 
in plots E and F the covariate effects were strong. The overlapping coefficient is an estimate 
of the percentage of overlapping area between the two density functions.
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Propensity score (PS) and disease risk score (DRS) distributions across treatment groups for 
one run of the simulation study with a sample size of 1,000 subjects and 100 covariates 
included in the PS and DRS models. In plots A and B the effects of covariates on both 
treatment and the outcome were mild, in plots C and D covariate effects were moderate, and 
in plots E and F the covariate effects were strong. The overlapping coefficient is an estimate 
of the percentage of overlapping area between the two density functions.
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propensity score (PS) and disease risk score (DRS) distributions across dabigatran and 
warfarin treatment groups for a 20% sample of the Medicare data and individuals with an 
index date between October 2010 and December 2012. In plots A and B the PS and DRS 
models included 37 a priori selected covariates, in plots C and D the PS and DRS models 
included 37 a priori selected covariates and 200 empirically selected covariates. The 
overlapping coefficient is an estimate of the percentage of overlapping area between the two 
density functions.
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propensity score (PS) and disease risk score (DRS) distributions across dabigatran and 
warfarin treatment groups for a 1% sample of the Medicare data and individuals with an 
index date between October 2010 and December 2012. In plots A and B the PS and DRS 
models included 37 a priori selected covariates, in plots C and D the PS and DRS models 
included 37 a priori selected covariates and 200 empirically selected covariates. The 
overlapping coefficient is an estimate of the percentage of overlapping area between the two 
density functions.
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Table 2
Baseline covariates measured during 1-year washout period
Warfarin (N=56,260) Dabigatran 150mg (N=11,407)
Demographics:
Age 78.91 76.76
Race (1 white, 0 other) (%) 89.2 91.72
Sex (% female) 42.17 48.95
Diagnoses: (%)
Cardiovascular:
 Chest pain 38.41 35.05
 Heart disease 74.56 66.62
 Heart failure 30.74 19.23
 Hypertension 65.08 63.30
 Hyperlipidemia 35.21 41.09
 Myocardial Infarction 3.49 1.89
 Cerebrovascular disease 21.29 17.38
Stroke
 Ischemic 6.09 4.31




Kidney disease 12.58 4.74






 ACE/ARB 52.22 50.23
 Loop diuretics 40.91 28.70
 Nonloop diuretics 52.55 41.97
Hypolipidemic drugs:
 Statins 49.40 52.45
 Fibrate 5.02 4.98
Rate Control Therapy:
 Beta blockers 70.83 71.99
 CCB 43.97 41.80
 Glycoside 18.49 17.10
Rhythm Control Therapy 19.10 23.21
Healthcare Use (average #):
# ECG claims 3.74 3.80
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Warfarin (N=56,260) Dabigatran 150mg (N=11,407)
# PSA claims 0.36 0.49
# of fecal occult blood tests 0.12 0.13
# colonoscopies 0.14 0.14
# flu shot claims 0.76 0.79
# of lipid assessments 1.52 1.72
# of mammography claims 0.25 0.29
# of PapSmear claims 0.05 0.07
TIA, transient ischemic attack; VTE, venous thromboembolism; ACE/ARB, angiotensin-converting enzyme/angiotensin II receptor blocker; CCB, 
calcium channel blockers; ECG, electrocardiography; PSA, prostate-specific antigen.
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